Novel drugs targeting retinoic acid receptors

JK Science

Volumn 7, Issue 1, 2005, Pages 55-56

  Sharma, Rashmi ^b,c   Sharma, Richa ^a   Verma, Ujala ^b   Bhat, Nusrat K ^b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b Poly Clinic Sunjwan Cantt   (India)

^c NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ALITRETINOIN; BEXAROTENE; ETRETIN; ETRETINATE; ISOTRETINOIN; PARATHYROID HORMONE; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RETINOID X RECEPTOR; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; SULFONE DERIVATIVE; SULFOXIDE; TAZAROTENE;

ALOPECIA; AORTA ANOMALY; BONE MALFORMATION; BRAIN PSEUDOTUMOR; CATARACT; CHEILITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CORNEA OPACITY; DARIER DISEASE; DEPRESSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRY NOSE; DRY SKIN; DYSLIPIDEMIA; EAR MALFORMATION; EPISTAXIS; ERYTHEMA; EYE IRRITATION; EYE MALFORMATION; FACE DYSMORPHIA; HEART SEPTUM DEFECT; HORMONE DEFICIENCY; HUMAN; HYDROCEPHALUS; KAPOSI SARCOMA; KERATODERMA; KERATOSIS PALMOPLANTARIS; LAMELLAR ICHTHYOSIS; LIVER DYSFUNCTION; MENTAL DEFICIENCY; MICROCEPHALY; NAIL DISEASE; PAPILLEDEMA; PARONYCHIA; PHOTOSENSITIVITY; PITYRIASIS RUBRA PILARIS; PREGNANCY; PREMATURE LABOR; PROTEIN TARGETING; PRURITUS; PSORIASIS; RECTUM HEMORRHAGE; RETINA DISEASE; RETINOL INTOXICATION; REVIEW; SKELETON MALFORMATION; SKIN APPENDAGE DISEASE; SKIN EXFOLIATION; SKIN IRRITATION; SKIN MANIFESTATION; SUICIDAL BEHAVIOR; T CELL LYMPHOMA; TERATOGENICITY;

EID: 20444391330     PISSN: 09721177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. Wei LN. Retinoid receptors and their co-regulators. Annu Rev Pharmacol Toxicol 2003; 43: 47-72.
2. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003; 49: 171-82.
3. Rang HP, Dale MM, Ritter JM, Moore PK. How drugs act: molecular aspects. In. Pharmacology 5th Ed. Publisher Elsevier Science Ltd. Churchill Livingstone-London 2003; pp 22-50.
4. Aboulafia DM, Norris D, Henry D, Grossman RJ, Thommes J, et al. 9-cis-Retinoic acid capsules in the treatment of AIDS-related Kaposi Sarcoma. Results of a phase 2 multi-centre clinical trial. Arch Dermatol 2003; 139: 178-86.
5. Weinstein GD, Koo JYM, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle controlled studies of the safety and efficacy of tazarotene 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48: 760-67.
6. Yu Z, Sefton J, Lew-Kaya DA, Walker PS, Yu D, Tang-Liu DDS. Pharmacokinetics of Tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with Acne Vulgaris or Photodamaged skin. Clin Pharmacokinet 2003; 42(10): 921-29.
7. McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM. Psoralen plus long-wave UV-A (PUVA) and Bexarotene therapy, an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003; 139: 771-75.